In treating ankylosing spondylitis, anti–tumor necrosis factor (anti-TNF) drugs produce a response in approximately 60% of patients. For the 40% of patients who do not respond to treatment, previous studies have suggested that patient characteristics, including sex, may play a role.
In treating ankylosing spondylitis (AS), anti—tumor necrosis factor (anti-TNF) drugs produce a response in approximately 60% of patients. For the 40% of patients who do not respond to treatment, previous studies have suggested that patient characteristics, including sex, may play a role.
Reporting findings in the International Journal of Rheumatic Diseases, investigators from the Netherlands sought to compare the long-term drug survival of anti-TNF therapies in men and women treated at a single large center in a retrospective study.
Data for all patients with AS who received etanercept, adalimumab, or infliximab between 2004 and 2014 (n = 122) were included in the analysis. The participants were 48 women (39.3%) and 74 men (60.7%). More patients used adalimumab (59.7%) than etanercept (28.9%) or infliximab (11.3%). After starting treatment, the mean follow-up duration was 5.1 years (range, 0.1-10.6).
Analysis over 10 years found that etanercept had the highest survival rate (85.3% after 3.7 years), followed by adalimumab and infliximab. In total, 22 patients (17.2%) eventually stopped treatment without starting a new therapy, and 32 (26.2%) switched to another anti-TNF agent. Treatment discontinuation was due primarily to inefficacy (in 21 patients; 52.4%) or adverse events (AEs), especially infections.
Women had significantly lower treatment survival than men, at 33.4 months versus 44.9 months (P = .031; 95% CI, 1.1-22). Among patients who switched to another drug, women switched more frequently than men (26.9% vs 16.3%), and with respect to AEs, women had a 26.1% change of developing infections compared with an 18.7% risk for men. Although not statistically significant, women completely stopped anti-TNF therapy more often than men did (20.8% vs 14.9%).
Given the fact that women had shorter treatment periods and also appeared to be more prone to infections, say the authors, it will be important to assess the possible associations of infection rates with sex in order to find strategies that could increase drug survival for women patients with AS who do respond to anti-TNF therapy.
Reference
Rusman T, ten Wolde S, Euser SM, van der Ploeg T, van Hall O, van der Horst-Bruninsma IE. Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice. Int J Rheum Dis. 2018;21(4):836-842. doi: 10.1111/1756-185X.13271.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.